13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001274413
Total reported value
$143.3M
$143.3M
82 檔
23.8%
In Q3 2025, Sectoral Asset Management Inc's U.S. equity holdings reached a combined market value of $143.3M, distributed across 82 disclosed stock positions.
Sectoral Asset Management Inc executed strategic sector rebalancing during Q3 2025, establishing 22 new positions while fully exiting 24 holdings and trimming 26 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 5.81% | +0.45% | — | |
| 2 | LLY | Eli Lilly & Co | Stock-Healthcare | 4.42% | +0.48% | +4.46% | |
| 3 | GPCR | Structure Therapeutics Inc | Stock-Other | 3.83% | -0.43% | +331.92% | |
| 4 | ANAB | Anaptysbio Inc | Stock-Other | 3.68% | — | +131.81% | |
| 5 | SI | Shoulder Innovations Inc | Stock-Other | 3.33% | +0.91% | — | |
| 6 | RCUS | Arcus Biosciences Inc | Stock-Other | 3.09% | +1.53% | +43.07% | |
| 7 | ✓ | Immatics NV | Stock-Other | 2.95% | +1.02% | +68.69% | |
| 8 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 2.89% | +0.49% | -19.11% | |
| 9 | BCAX | Bicara Therapeutics Inc | Stock-Other | 2.60% | — | +32.32% | |
| 10 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 2.43% | -0.10% | +41.98% | |
| 11 | SLDB | Solid Biosciences Inc | Stock-Other | 2.41% | — | +50.16% | |
| 12 | KURA | Kura Oncology Inc | Stock-Other | 2.16% | +0.05% | +22.34% | |
| 13 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 2.13% | — | +18.85% | |
| 14 | ABBV | Abbvie Inc | Stock-Healthcare | 2.12% | -0.06% | — | |
| 15 | MBX | Mbx Biosciences Inc | Stock-Other | 2.11% | — | +1.60% | |
| 16 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 2.10% | — | — | |
| 17 | ZBIO | Zenas Biopharma Inc | Stock-Other | 2.08% | — | -27.82% | |
| 18 | PVLA | Palvella Therapeutics Inc | Stock-Other | 1.90% | — | -48.63% | |
| 19 | TECX | Tectonic Therapeutic Inc | Stock-Other | 1.87% | +1.18% | +94.78% | |
| 20 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 1.86% | -0.98% | +11.09% | |
| 21 | AMGN | Amgen Inc | Stock-Healthcare | 1.80% | -0.58% | -8.25% | |
| 22 | TIL | Instil Bio Inc | Stock-Other | 1.78% | — | +87.17% | |
| 23 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.77% | -0.44% | -4.77% | |
| 24 | JNJ | Johnson & Johnson | Stock-Healthcare | 1.75% | -0.46% | -20.73% | |
| 25 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 1.59% | -0.38% | +9.52% | |
| 26 | ONC | Beone Medicines Ltd-adr | Stock-Other | 1.51% | -0.15% | -6.67% | |
| 27 | ABT | Abbott Laboratories | Stock-Healthcare | 1.42% | -1.04% | +13.16% | |
| 28 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 1.38% | -1.12% | +43.09% | |
| 29 | GILD | Gilead Sciences Inc | Stock-Healthcare | 1.34% | -1.60% | -0.71% | |
| 30 | BSX | Boston Scientific CORP | Stock-Healthcare | 1.33% | -0.73% | +4.73% | |
| 31 | DHR | Danaher CORP | Stock-Healthcare | 1.30% | -0.23% | — | |
| 32 | PFE | Pfizer Inc | Stock-Healthcare | 1.21% | -0.18% | — | |
| 33 | INSM | Insmed Inc | Stock-Healthcare | 1.19% | -1.07% | -9.78% | |
| 34 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 1.17% | -0.20% | — | |
| 35 | QURE | uniQure N.V. | Stock-Other | 1.11% | -0.41% | EXIT | |
| 36 | BNTX | Biontech Se-adr | Stock-Other | 1.07% | +1.03% | +9.28% | |
| 37 | SYK | Stryker CORP | Stock-Healthcare | 0.98% | -0.03% | +10.26% | |
| 38 | SMMT | Summit Therapeutics Inc | Stock-Other | 0.94% | +1.08% | +13.57% | |
| 39 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 0.92% | -0.23% | -1.50% | |
| 40 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 0.89% | — | +0.59% | |
| 41 | DXCM | Dexcom Inc | Stock-Healthcare | 0.86% | +1.18% | +56.82% | |
| 42 | MRK | Merck & Co. Inc. | Stock-Healthcare | 0.86% | -0.20% | -21.53% | |
| 43 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 0.84% | -0.12% | +6.37% | |
| 44 | RAPP | Rapport Therapeutics Inc | Stock-Other | 0.80% | -0.69% | EXIT | |
| 45 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.79% | -0.47% | -91.14% | |
| 46 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.75% | -0.41% | +25.48% | |
| 47 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 0.72% | -0.21% | — | |
| 48 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 0.68% | -0.13% | -0.70% | |
| 49 | ✓ | Merus N V | Stock-Other | 0.67% | — | -26.35% | |
| 50 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.60% | +0.07% | -21.02% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | GPCR | Structure Therapeutics Inc | +3.4% | +331.92% | Add |
| 2 | RCUS | Arcus Biosciences Inc | +2.9% | +43.07% | Add |
| 3 | ORIC | Oric Pharmaceuticals Inc | +2.3% | +41.98% | Add |
| 4 | CTNM | Contineum Therapeutics Inc-a | +1.5% | — | Unchanged |
| 5 | ONC | Beone Medicines Ltd-adr | +0.9% | -6.67% | Add |
| 6 | QURE | uniQure N.V. | +0.6% | -44.56% | Trim |
| 7 | ARGX | Argenx Se - Adr | +0.3% | -4.77% | Add |
| 8 | AVBP | Arrivent Biopharma Inc | +0.3% | +10.27% | Add |
| 9 | INSM | Insmed Inc | +0.3% | -9.78% | Trim |
| 10 | TRVI | Trevi Therapeutics Inc | +0.2% | -21.02% | Add |
| 11 | ASND | Ascendis Pharma A/S | +0.2% | +3.75% | Add |
| 12 | IONS | Ionis Pharmaceuticals Inc | +0.2% | — | Trim |
| 13 | TEM | Tempus Ai Inc-cl A | +0.1% | — | Add |
| 14 | ROIV | Roivant Sciences Ltd. | +0.1% | — | Add |
| 15 | VRTX | Vertex Pharmaceuticals Inc | +0.1% | +11.09% | Add |
| 16 | DXCM | Dexcom Inc | +0.1% | +56.82% | Add |
| 17 | PFE | Pfizer Inc | 0% | — | Add |
| 18 | MDGL | Madrigal Pharmaceuticals Inc | 0% | — | Unchanged |
| 19 | UTHR | United Therapeutics CORP | 0% | — | Unchanged |
| 20 | REGN | Regeneron Pharmaceuticals | 0% | +43.09% | Add |
| 21 | VERA | Vera Therapeutics Inc | 0% | -27.11% | Add |
| 22 | BBIO | Bridgebio Pharma Inc | 0% | -15.14% | Trim |
| 23 | NBIX | Neurocrine Biosciences Inc | 0% | — | Add |
| 24 | TARS | Tarsus Pharmaceuticals Inc | 0% | -0.70% | Add |
| 25 | PTCT | Ptc Therapeutics Inc | 0% | — | Add |
| 26 | AXSM | Axsome Therapeutics Inc | 0% | — | Unchanged |
| 27 | RPRX | Royalty Pharma plc | 0% | — | Unchanged |
| 28 | MRNA | Moderna Inc | 0% | — | Unchanged |
| 29 | JAZZ | Jazz Pharmaceuticals plc | 0% | -1.32% | Trim |
| 30 | ILMN | Illumina Inc | -0.1% | -1.98% | Trim |
| 31 | TMO | Thermo Fisher Scientific Inc | -0.1% | — | Add |
| 32 | BIIB | Biogen Inc | -0.1% | — | Trim |
| 33 | SMMT | Summit Therapeutics Inc | -0.1% | +13.57% | Add |
| 34 | AM6 | Amicus Therapeutics Inc | -0.1% | -0.40% | Add |
| 35 | INCY | Incyte CORP | -0.1% | -50.00% | Trim |
| 36 | BNTX | Biontech Se-adr | -0.1% | +9.28% | Add |
| 37 | ALNY | Alnylam Pharmaceuticals Inc | -0.2% | -1.50% | Trim |
| 38 | AZNN | Astrazeneca Plc-spons Adr | -0.2% | +0.59% | Trim |
| 39 | CYTK | Cytokinetics Inc | -0.2% | -12.80% | Trim |
| 40 | BOLD | Boundless Bio Inc | -0.3% | — | Unchanged |
| 41 | ABBV | Abbvie Inc | -0.3% | — | Unchanged |
| 42 | RDNT | Radnet Inc | -0.3% | -20.00% | Trim |
| 43 | DHR | Danaher CORP | -0.4% | — | Unchanged |
| 44 | ISRG | Intuitive Surgical Inc | -0.4% | +9.52% | Add |
| 45 | BMRN | Biomarin Pharmaceutical Inc | -0.5% | +6.37% | Add |
| 46 | MLTX | Moonlake Immunotherapeutics | -0.5% | -93.67% | Trim |
| 47 | SPRY | Ars Pharmaceuticals Inc | -0.5% | +24.32% | Trim |
| 48 | ABT | Abbott Laboratories | -0.5% | +13.16% | Trim |
| 49 | PCVX | Vaxcyte Inc | -0.5% | — | Trim |
| 50 | BSX | Boston Scientific CORP | -0.6% | +4.73% | Trim |
According to official SEC Form 13F filings, Sectoral Asset Management Inc reported a total U.S. public equity portfolio value of $143.3M across 82 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including CTNM, LLY, GPCR) accounted for 23.8% of total reported equity market value during Q3 2025.
Top New Position Initiated
ANAB
市值: $6.0M
Top Position Liquidated / Trimmed
LENZ
前期市值: $25.1M
During Q3 2025, Sectoral Asset Management Inc's top holdings by market value included CTNM (5.8%)、LLY (4.4%)、GPCR (3.8%). The largest single position, CTNM, represented 5.8% of total portfolio value.
In Q3 2025, Sectoral Asset Management Inc made 97 total portfolio adjustments, initiating 22 new buys, adding to 25 positions, trimming 26 holdings, and fully liquidating 24 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.